梁国华,张清媛,赵文辉.雌激素受体阳性乳腺癌中长链非编码RNA与他莫昔芬耐药关系的研究进展[J].中国肿瘤,2018,27(9):690-694.
雌激素受体阳性乳腺癌中长链非编码RNA与他莫昔芬耐药关系的研究进展
Research Progress on Relationship Between LncRNA and Tamoxifen Resistance in ER Positive Breast Cancer
投稿时间:2018-04-27  
DOI:10.11735/j.issn.1004-0242.2018.09.A010
中文关键词:  雌激素受体(ER)  乳腺癌  他莫昔芬  耐药  长链非编码RNA
英文关键词:estrogen receptor (ER)  breast cancer  tamoxifen  resistance  long non-coding RNA (lncRNA)
基金项目:
作者单位
梁国华 哈尔滨医科大学附属肿瘤医院 
张清媛 哈尔滨医科大学附属肿瘤医院 
赵文辉 哈尔滨医科大学附属肿瘤医院 
摘要点击次数: 2013
全文下载次数: 383
中文摘要:
      摘 要:长链非编码RNA(long non-coding RNA,lncRNA)是非编码RNA的一个大类,其在多种肿瘤中异常表达。近年来,不少研究发现lncRNA,如ROR、HOTAIR、UCA1、BCAR4,在雌激素受体阳性(ER+)乳腺癌的他莫昔芬耐药中发挥了重要作用。因此,了解lncRNA在他莫昔芬耐药中的生物学机制具有重要的临床意义。该文就lncRNA与ER+乳腺癌他莫昔芬耐药的相关研究展开综述,为ER+乳腺癌他莫昔芬耐药的预防及治疗提供新思路。
英文摘要:
      Abstract:Long non-coding RNA (lncRNA) is a large class of non-coding RNA,which is abnormal in multiple tumors. In recent years,many studies have found that lncRNAs,such as ROR,HOTAIR,UCA1 and BCAR4,play an important role in drug resistance of tamoxifen in ER+ breast cancer. Therefore,it is of great clinical significance to understand the biological mechanism of lncRNA in tamoxifen resistance. In this article,the related studies of lncRNA and tamoxifen resistance in ER+ breast cancer are reviewed to provid new thoughts to the prevention and treatment for ER+ breast cancer with tamoxifen resistance.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器